Glaucoma: Early Signs, Risk Factors, and When to Get Checked

Glaucoma is often described as a quiet threat to sight, sometimes called a "silent thief," because the most common forms can damage the optic nerve for years before everyday vision feels different. The NHS explains glaucoma as an eye condition in which the main nerve connecting the eye to the brain becomes damaged, most often in adults aged 50 and over. The National Eye Institute (NEI) of the National Institutes of Health and the American Academy of Ophthalmology (AAO) frame it as a group of diseases that can cause vision loss and blindness by damaging that same optic nerve. Raised pressure inside the eye is frequently involved, but it is not the whole story: some people develop glaucoma with pressure in a "normal" range, and some people with high pressure never develop glaucoma damage.

What makes glaucoma especially important for patients is the combination of silence and permanence. Damage usually begins in peripheral (side) vision, which is hard to notice day to day. Once sight is lost, major patient sources agree it cannot be restored. There is no cure, but treatments that lower eye pressure can slow or stop further damage and protect remaining vision, especially when disease is found early. The World Health Organization (WHO) lists glaucoma among leading causes of distance vision impairment and blindness globally and attributes 7.7 million cases of that impairment or blindness to glaucoma, as WHO states. That is a burden figure, not a personal diagnosis rule.

Prevalence and awareness numbers also need careful attribution rather than one invented global rate. The College of Optometrists states that primary open-angle glaucoma (POAG), the most common UK type, affects about 2% of people over 40 and about 4-5% over 80, as the College states. NICE information for the public notes that glaucoma is most often seen in people in their 70s or older, and that about 1 in 10 people registered as blind lost sight because of glaucoma, while only a small proportion of people with glaucoma lose sight altogether. NEI and AAO both report that about half of people with glaucoma do not know they have it.

This article covers open-angle versus angle-closure patterns, why early disease is often silent, risk factors, red flags, when to get checked, exams, and high-level drops, laser, and surgery, without dosing or DIY steps.

What Glaucoma Is: Optic Nerve Damage, and Why Pressure Isn't the Whole Story

Optic nerve damage, not just "high pressure"

Glaucoma is fundamentally about the optic nerve, the cable of nerve fibres that carries visual signals from the eye to the brain. The NHS, NEI, AAO, the Royal College of Ophthalmologists (RCOphth) patient booklet (with RNIB), the College of Optometrists, and NICE Clinical Knowledge Summaries (CKS) all describe progressive optic-nerve damage, often with characteristic visual-field defects and optic-nerve-head changes. Fluid (aqueous humour) normally drains from the front of the eye; when drainage is impaired, pressure can rise and contribute to nerve damage. AAO explains that blind spots develop as nerve fibres die, and people may not notice until many fibres are already gone.

Pressure is common: but not required

Many people with glaucoma have raised intraocular pressure (IOP), and treatments that lower pressure help slow the disease (NEI, AAO, NHS, RCOphth). At the same time:

• Normal-tension / normal-pressure glaucoma can damage the nerve when pressure is within a typical range. RCOphth notes the nerve may be more fragile or sensitive in some people.
• Ocular hypertension (OHT) means consistently or recurrently elevated IOP without signs of glaucoma damage. NICE CKS (July 2025) defines OHT as elevated IOP above 21 mmHg with no glaucoma signs. That is a clinician definition, not a home self-check rule.
• RCOphth's patient booklet gives an educational "normal" IOP range of roughly 10-21 mmHg. NICE guidance discussions for case-finding and treatment often use clinician thresholds such as 24 mmHg. These figures are source-attributed educational or guideline numbers. They are not instructions for interpreting a single air-puff reading at home, and they are not a do-it-yourself target-pressure algorithm.

High pressure does not always equal glaucoma. Normal pressure does not always equal safety. Results are interpreted together with the optic nerve, visual fields, corneal thickness, drainage angle, and imaging when used.

No cure: protect what remains

NHS, NEI, AAO, and RCOphth agree there is no cure and that lost vision cannot be reversed. Early detection and ongoing treatment aim to slow damage and help most treated people keep useful vision. NICE shared-decision messages similarly emphasise that early disease is often symptomless, that most treated people will not go blind, and that sight once lost is not recovered.

Open-Angle vs Angle-Closure Glaucoma (High Level)

Open-angle: most common in many populations

Open-angle glaucoma (also called primary or chronic open-angle glaucoma, or POAG / COAG in UK materials) is the most common pattern in the UK and United States. AAO uses a gradual "clogged drain" metaphor: the drainage angle looks open, but fluid leaves too slowly. Disease usually progresses painlessly over years with no early vision change. NEI estimates open-angle accounts for about 9 in 10 US glaucoma cases. Normal-tension glaucoma is a form of open-angle disease with normal pressure (NEI, RCOphth).

Angle-closure: chronic or acute

Angle-closure (also called closed-angle, narrow-angle, or acute glaucoma in some patient language) occurs when the iris can block the drainage angle. It may be:

• Chronic / slow: often silent early (AAO, NEI, RCOphth).
• Acute: sudden pressure rise; a sight-threatening emergency that, untreated, can cause blindness in a few days (NEI). NHS, AAO, College of Optometrists, and RCOphth all treat acute angle-closure crisis as same-day emergency care.

The College of Optometrists describes a ladder from angle-closure suspect features through raised pressure or adhesions without nerve damage to primary angle-closure glaucoma with nerve damage. Angle-closure is rarer than POAG in the UK but carries greater risk of vision damage; it is more often discussed in women, long-sighted people, and people of East Asian ancestry, and risk rises with age (College; RCOphth).

Secondary and childhood forms (briefly)

Secondary glaucoma can follow another eye disease, injury, inflammation, cataracts or tumours in some cases, or medicines such as steroids (NEI, RCOphth, NHS).

Why Early Glaucoma Is Often Silent, and Why Eye Exams Matter

No early warning for the commonest forms

Open-angle glaucoma, and often chronic angle-closure, usually has no early warning symptoms. The NHS says most people do not realise they have it; disease develops slowly over many years and is usually found on routine eye tests. RCOphth stresses that you typically cannot "feel" POAG. AAO's "silent thief of sight" framing matches NEI's message that symptoms can start so slowly you may not notice. The College of Optometrists notes POAG is not painful and patients may be unaware until vision loss has begun.

Pressure-only screening is not enough

Finding glaucoma means looking at more than a single pressure number. AAO and NEI emphasise that pressure-only screening is insufficient; a comprehensive exam, often including a dilated look at the optic nerve, visual-field testing, and related checks, is how disease is detected. NICE NG81 advises clinicians not to base referral solely on non-contact (air-puff) tonometry IOP. NEI's detection statement likewise says tonometry alone is not sufficient.

Population screening evidence versus practical exams

A Cochrane review (CD006129) found no RCTs of population-based open-angle glaucoma screening and concluded such programmes cannot be recommended on that evidence, while still encouraging higher-risk people to seek testing. That is not a reason to ignore eye care: NHS, NEI, and AAO emphasise regular comprehensive exams, especially if higher risk. Mass population-screening RCT evidence is weak; opportunistic comprehensive exams are what major patient sources recommend.

Who Is at Higher Risk

Risk rises with age and with family history, especially first-degree relatives. Multiple risk factors raise risk further (AAO). Ethnicity wording differs by source and should stay attributed rather than merged into one invented global sentence.

Age, family, and pressure-related risks

• Age: NHS: more common over 50. AAO: complete eye exam around age 40, with more frequent follow-up if risk factors. NEI: higher-risk bands include African Americans ≥40 and everyone >60 (especially Mexican Americans / Hispanic-Latino framing on NEI pages). RCOphth: POAG prevalence may rise from up to about 2 in 100 over 40 toward up to about 7 in 100 over 70, as that booklet states. College of Optometrists: greater-than-average POAG risk from >40, rising each decade.
• Family history: NHS, NEI, AAO, NICE BNF, College, and RCOphth all list first-degree relatives. RCOphth attributes roughly eightfold sibling risk and about twofold parent risk for POAG. Those are RCOphth-attributed multipliers, not universal self-rules.
• High eye pressure / OHT: AAO, BNF, RCOphth, College; OHT is a high-risk state for developing COAG (BNF).
• Thin central cornea and optic-nerve thinning (AAO); thinner corneas also on College risk guidance.
• Myopia (short-sight) associated with open-angle risk; hyperopia (long-sight) with angle-closure risk (NHS, AAO, RCOphth); College notes myopia greater than 6 dioptres as associated with higher POAG risk (College-specific framing).

Ethnicity: attribute each source

• NHS: Black African, Caribbean, or Asian background.
• NEI: African American and over 40; over 60 especially Hispanic/Latino.
• AAO: African, Hispanic, or Asian heritage.
• RCOphth: African Caribbean ancestry about 2-3× POAG risk and may start before 40; East Asian ancestry raises angle-closure risk.
• College of Optometrists: African-Caribbean for greater POAG risk; South or East Asian descent for angle-closure prevalence higher than COAG.

Other medical and medicine-related factors

AAO lists diabetes, migraines, high blood pressure, poor circulation, or other whole-body vascular problems (see also Diabetes and Heart Disease: The Cardiovascular Connection; Type 1 vs Type 2 Diabetes: Understanding the Key Differences). RCOphth attributes about twofold diabetes-related POAG risk. College and BNF also list diabetes and systemic hypertension / cardiovascular disease among risks. Long-term steroid use (topical or systemic) and eye injury appear across NHS, AAO, RCOphth, College, and BNF. NEI notes higher normal-tension glaucoma risk with Japanese ancestry, family history of NTG, certain heart problems (for example irregular heartbeat), and low blood pressure.

In the UK, RCOphth notes that close relatives over 40 of someone with glaucoma should have a free NHS eye exam every year. That is a UK entitlement framing, not a global insurance rule.

Symptoms to Know, and Acute Angle-Closure Red Flags

Chronic open-angle: late peripheral loss

Chronic open-angle glaucoma usually has no early symptoms. Later, people may develop peripheral blind spots or side-vision loss that is easy to miss (NEI, AAO, NHS). Symptom lists are not a home diagnosis; other conditions can cause red or painful eyes (NHS mentions examples such as uveitis or eye injury).

Mild warning symptoms before some angle-closure attacks

AAO and RCOphth describe milder pre-attack symptoms in some people: blurred or misty vision, rainbow rings or halos around lights, aching eyes (RCOphth notes evenings especially), or mild headache or eye pain. Those warning signs warrant prompt optometrist or eye-care review. Do not wait for a full acute attack (AAO, RCOphth).

Acute angle-closure: emergency

Sudden severe features commonly listed by NHS, NEI, AAO, RCOphth, College of Optometrists, and NICE BNF include:

• Intense eye pain or severe forehead/eye pain
• Red eye and tenderness
• Blurred or rapidly worsening vision
• Rainbow circles / halos around bright lights
• Headache
• Nausea or vomiting

This is a sight-threatening emergency. Pathway framing differs by country: in the UK, NHS advises calling 999 or going to A&E if symptoms develop suddenly; RCOphth advises A&E or eye casualty immediately; the College of Optometrists advises same-day ophthalmology emergency referral. In the US, NEI and AAO advise seeing a doctor or going to an emergency room now. Local emergency services apply wherever you are.

Acute angle-closure care typically involves emergency medicines to lower pressure, then usually laser iridotomy (often discussed for both eyes as prophylaxis). This notes the existence of that pathway only; this article does not describe technique or home pressure management.

For non-urgent vision worries, NHS advises seeing a GP or optician. If a diagnosis plan or treatment choice feels unsettled after discussion, some people also consider What Is a Medical Second Opinion and Why It Matters.

When and How Often to Get Checked

Practical intervals: jurisdiction and risk dependent

Regular comprehensive eye exams are the practical way to find glaucoma early. Intervals are not a single universal calendar:

• NHS: eye tests at least every 2 years; more often if higher risk (for example a parent or sibling with glaucoma), usually via an optometrist at local opticians.
• NEI: if higher risk, comprehensive dilated exam every 1-2 years; ask your doctor how often is right for you. Higher-risk groups on NEI's detection statement include African Americans ≥40, everyone >60 (especially Mexican Americans), and people with family history. More frequent exams apply if there is imminent optic-nerve damage risk.
• AAO: adults should have a complete eye exam around age 40; risk factors mean more frequent visits as the ophthalmologist recommends.
• RCOphth (UK): your optometrist advises frequency based on age, family history, and other risks; relatives over 40 of someone with glaucoma: yearly free NHS exam (UK).

NICE NG81 advises people with IOP below clinician case-finding thresholds (discussions often reference 24 mmHg in that guideline context) to continue regular primary eye-care visits. NICE also publishes clinician reassessment interval tables for treated OHT, suspects, and COAG. Those tables are for specialist use, not patient DIY schedules. AAO notes that once on medicines, visits are often about every 3-6 months, varying by case, again clinician-directed.

Do not convert pressure thresholds into a home tonometry rule. Cochrane's weak population-screening RCT evidence does not cancel opportunistic comprehensive exams recommended by NHS, NEI, and AAO.

What Happens at an Eye Exam if Glaucoma Is Suspected

Tests clinicians may use: interpreted together

If an optometrist or other clinician suspects glaucoma or ocular hypertension, you may be referred to an ophthalmologist for further assessment (NHS). Typical elements described by AAO, NEI, RCOphth, and NICE NG81, framed as what a clinician may do, not a checklist to demand, include:

• History and risk-factor discussion
• IOP measurement: NICE prefers Goldmann-type applanation tonometry for referral decisions; do not rely on a single non-contact reading alone
• Optic nerve examination, often with dilation; photos or baseline imaging
• Visual field testing for peripheral vision
• Central corneal thickness (pachymetry)
• Drainage-angle assessment (gonioscopy or alternatives)
• Imaging such as optical coherence tomography (OCT) of the nerve

Treatment Overview: Drops, Laser, and Surgery (No Dosing or DIY)

Goal: lower pressure to protect remaining sight

Treatment aims to lower eye pressure enough to protect the optic nerve and prevent further vision loss, not to restore sight already lost (NHS, NEI, AAO, RCOphth, NICE). RCOphth describes a "target eye pressure" as a clinician concept for that person; this article does not publish numeric target tables. Your eye-care professional chooses treatment and follow-up.

Eye drops: common long-term treatment

Pressure-lowering eye drops remain the most common ongoing treatment in many settings and are often long-term or lifelong (NHS, NEI, AAO). Drops may reduce fluid production or help drainage. NEI and AAO emphasise starting treatment promptly, taking medicines every day as prescribed, reporting side effects, and not stopping or changing drops without clinical advice. NICE shared-decision points similarly stress adherence.

Clinicians may prescribe medicines from classes used in NHS, NICE, and BNF materials, for example prostaglandin analogues (BNF/NICE pharmacological first-line framing when laser is declined, unsuitable, or insufficient), and other classes as needed. Naming a class or an example already used by those sources is for orientation only. This article does not publish doses, frequencies, or "which bottle to buy."

Laser: region and guideline era matter for "first-line"

Laser options exist at a high level:

• Selective laser trabeculoplasty (SLT) / laser trabeculoplasty for many open-angle cases. It helps fluid drain (NEI, AAO, RCOphth, NICE).
• Laser iridotomy for angle-closure pathways, typically after emergency pressure control in acute presentations (RCOphth, NEI, AAO); technique is not described here.

First-line conflict: attribute both sides. UK NICE NG81 (including the 2022 SLT update), NICE BNF, and the RCOphth patient booklet emphasise offering 360° SLT as first-line for many newly diagnosed OHT cases with clinician-defined lifetime visual-impairment risk and for many newly diagnosed non-advanced COAG cases (excluding pigment-dispersion patterns as NICE specifies), with generic prostaglandin-analogue drops as pharmacological first-line when SLT is declined, unsuitable, or not enough. US patient pages from NEI and AAO still commonly describe drops as the most common starting treatment, with laser as an option. That difference is region- and guideline-dependent. The clinician decides; this article does not pick one "correct" first-line for every reader worldwide.

A Cochrane review of laser trabeculoplasty (CD003919) reports that laser may work better than topical medicines for slowing visual-field progression and may be similar to modern drops for IOP control at lower cost, with fewer serious harms especially with newer SLT, while working less well than trabeculectomy. Treat that as uncertainty language for shared decisions, not a DIY ranking.

Surgery when drops or laser are not enough

If medicines and laser are insufficient, or disease is advanced, surgical options may be discussed, including trabeculectomy, drainage devices/shunts, and other approaches including some minimally invasive options in specialist pathways (NHS, AAO, RCOphth, NICE). NICE discusses surgery with mitomycin C for advanced COAG in guideline terms. No procedure how-to appears here.

Conclusion

Glaucoma damages the optic nerve; raised pressure is often involved but neither required nor sufficient alone. Open-angle disease is usually silent; acute angle-closure is an emergency. Lost vision cannot be restored. Treatment protects remaining sight via clinician-chosen drops, laser, or surgery, with regional first-line differences attributed rather than unified.

Medical Disclaimer

Content on MED.COM is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with questions about a medical condition. Never disregard professional medical advice or delay seeking it because of something read on this site. If you think you may have a medical emergency, contact local emergency services immediately.